HC Wainwright Lifts Price Target for Eton Pharmaceuticals Stock

Research firm sees strong upside potential for the specialty drugmaker's shares.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

HC Wainwright, a research and investment banking firm, has raised its price target for Eton Pharmaceuticals (NASDAQ:ETON) from $35 to $37 per share. The firm maintained its "buy" rating on the stock, citing the company's promising pipeline of specialty pharmaceutical products.

Why it matters

Eton Pharmaceuticals is a small-cap pharmaceutical company focused on developing and commercializing drugs for rare and underserved medical conditions. An increased price target from a respected research firm like HC Wainwright suggests Wall Street sees significant upside potential in the company's stock, which could boost investor confidence and attract more attention to the company.

The details

In its research report, HC Wainwright cited Eton Pharmaceuticals' diverse product portfolio, which includes thyroid hormone replacements and a drug for toxoplasmosis. The firm believes the company's pipeline and commercial execution capabilities position it for strong growth in the coming years.

  • HC Wainwright issued its updated research report on Eton Pharmaceuticals on Monday, March 2, 2026.

The players

Eton Pharmaceuticals

A specialty pharmaceutical company focused on developing and commercializing drugs for rare and underserved medical conditions.

HC Wainwright

A research and investment banking firm that covers Eton Pharmaceuticals and has issued a "buy" rating on the stock.

Got photos? Submit your photos here. ›

The takeaway

The increased price target from HC Wainwright suggests Wall Street sees significant growth potential in Eton Pharmaceuticals, a small-cap pharmaceutical company with a diverse pipeline of specialty drugs. This could help boost investor interest and confidence in the stock.